52 completed, 13 recruiting, 13 unknown, 7 active not recruiting. 38 Phase 2, 18 Phase 1, 13 Not applicable, 9 Phase 3, 1 Early Phase 1.
Follow Neoplasms, Unknown Primary: new trials by email Literature Review of Neoplasms, Unknown Primary trials Research Report on Neoplasms, Unknown Primary
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Smartphone-Based Self-Registration of Health Data in Patients With Severe Unspecific Symptoms or Cancer of Unknown Primary Smartphone app enabling self-registration of physical and mental health - Advanced Unspecific Symptom, Cancer of Unknown Primary Site | Not applicable | Not yet recruiting | University of Skövde | 200 | 2026-12-01 | 2026-10-27 |
| Living Without Answers - ILLUMINATE CUP Cancer, CUP | Not yet recruiting | The Clatterbridge Cancer Centre NHS Foundation Trust | 20 | 2026-09-01 | 2026-07-20 | |
| A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP) F520 combined with chemotherapy, placebo combined with chemotherapy - Cancer of Unknown Primary Site | Phase 2 / Phase 3 | Recruiting | Shandong New Time Pharmaceutical Co., LTD | 402 | 2026-07-08 | 2026-08-12 |
| Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK) Breast Cancer, Lung Cancer | Recruiting | University Health Network, Toronto | 7000 | 2026-03-31 | 2026-08-21 | |
| 18F-FAPI PET in Cancers of Unknown Primary Site 18F-FAPI PET - Cancer of Unknown Primary Site | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 120 | 2026-02-01 | 2026-01-28 | |
| The NorCUP Trial: Improving Prognosis and Personalized Treatment in Cancer of Unknown Primary (CUP) Comprehensive molecular profiling - Cancer of Unknown Primary Site | Not applicable | Not yet recruiting | Haukeland University Hospital | 350 | 2026-01-01 | 2026-01-26 |
| Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs Stage III Breast Cancer, Stage IV Breast Cancer | Withdrawn | Travera Inc | 2024-11-01 | 2024-11-25 | ||
| Enabling Genomic Testing in Cancer of Unknown Primary Gene panel array, Blood Sample Collection - Cancer of Unknown Primary, Neoplasm, Unknown Primary | Recruiting | The Christie NHS Foundation Trust | 100 | 2024-08-15 | 2026-03-25 | |
| A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY) Pegsitacianine - Head and Neck Cancer, Unknown Primary Cancer | Phase 2 | Recruiting | University of Texas Southwestern Medical Center | 120 | 2024-04-17 | 2026-04-14 |
| PaCIFiC-CUP Classifies Cancer of Unknown Primary Unknown Primary Tumors, DNA Methylation | Recruiting | Sun Yat-sen University | 120 | 2023-07-01 | 2026-04-23 | |
| Real-time Targeted Fluorescence Endoscopy for Detection of the Primary Cancer Lesion in Patients With a Metastasis of Unknown Primary Tumor in the Head and Neck Detection of lesions using fluorescence molecular imaging - Unknown Primary Tumors, Oropharynx Cancer | Not applicable | Unknown | University Medical Center Groningen | 35 | 2023-04-28 | 2023-10-25 |
| Surgeon-performed Intraoperative Transoral Ultrasound for Cancer of Unknown Primary Transoral Ultrasound - Cancer of Unknown Primary Site, Unknown Primary Cancer | Not applicable | Completed | Copenhagen University Hospital, Rigshospitalet | 30 | 2023-02-21 | 2024-05-07 |
| Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) Pleural Effusion, Malignant, Ascites, Malignant | Completed | Travera Inc | 72 | 2022-07-15 | 2026-04-13 | |
| FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown Primary 68Ga-FAPi-46, PET/CT imaging - Cancer of Unknown Primary Site | Not applicable | Unknown | Peter MacCallum Cancer Centre, Australia | 150 | 2022-02-23 | 2023-03-31 |
| Solving Riddles Through Sequencing Next Generation Sequencing - Leukemia, Hematologic Malignancy | Recruiting | Munich Leukemia Laboratory | 100 | 2022-01-19 | 2026-10-09 | |
| Sintilimab in Cancer of Unknown Primary Sintilimab - Cancer of Unknown Primary Site | Phase 2 | Completed | M.D. Anderson Cancer Center | 10 | 2021-08-26 | 2026-02-25 |
| Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in China no intervention - Cancer of Unknown Primary Site | Unknown | Fudan University | 200 | 2021-06-18 | 2021-07-07 | |
| Carcinoma of Unknown Primary (CUP): a Comparison Across Tissue and Liquid Biomarkers Cancer of Unknown Primary Site | Completed | The Christie NHS Foundation Trust | 117 | 2021-06-09 | 2024-10-10 | |
| The Registry of Oncology Outcomes Associated With Testing and Treatment Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P) - Adenocarcinoma, Adenocystic Carcinoma | Completed | Taproot Health | 167 | 2021-05-05 | 2024-12-18 | |
| Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors Spartalizumab, Tislelizumab - MSI-H Colorectal Cancer, Melanoma | Phase 2 | Active not recruiting | SOLTI Breast Cancer Research Group | 184 | 2021-04-12 | 2025-03-21 |
Showing 20 of 101. Sign in to see all of them.
Breast Neoplasms (27) · Pancreatic Neoplasms (21) · Head and Neck Neoplasms (20) · Neoplasms (18) · Stomach Neoplasms (18) · Esophageal Neoplasms (17) · Melanoma (17) · Carcinoma, Non-Small-Cell Lung (16) · Colonic Neoplasms (16) · Carcinoma, Hepatocellular (15) · Carcinoma, Renal Cell (15) · Urinary Bladder Neoplasms (15) · Lung Neoplasms (14) · Prostatic Neoplasms (14)
Neoplastic Processes (101) · Pathologic Processes (101) · Pathological Conditions, Signs and Symptoms (101) · Neoplasm Metastasis (95) · Neoplasms (83) · Neoplasms by Site (54) · Neoplasms by Histologic Type (47) · Neoplasms, Glandular and Epithelial (42) · Digestive System Diseases (38) · Digestive System Neoplasms (37) · Carcinoma (34) · Gastrointestinal Diseases (34) · Female Urogenital Diseases (32) · Female Urogenital Diseases and Pregnancy Complications (32) · Skin Diseases (32)
Carboplatin (12) · Gemcitabine (11) · Paclitaxel (11) · Capecitabine (7) · Irinotecan (6) · Cisplatin (5) · Fluorouracil (5) · Bevacizumab (4) · Leucovorin (4) · Oxaliplatin (4) · Radiotherapy (4) · Cyclophosphamide (3) · Erlotinib Hydrochloride (3) · Etoposide (3) · Filgrastim (3)
M.D. Anderson Cancer Center (6) · SCRI Development Innovations, LLC (5) · Copenhagen University Hospital, Rigshospitalet (4) · University Health Network, Toronto (4) · Memorial Sloan Kettering Cancer Center (3) · National Cancer Institute (NCI) (3) · The Christie NHS Foundation Trust (3) · Alliance for Clinical Trials in Oncology (2) · Eastern Cooperative Oncology Group (2) · Fudan University (2) · Mayo Clinic (2) · NYU Langone Health (2) · Travera Inc (2) · AHS Cancer Control Alberta (1) · Academisch Ziekenhuis Maastricht (1)
United States (51) · China (9) · Denmark (8) · Canada (7) · United Kingdom (7) · Germany (5) · Netherlands (5) · Australia (3) · France (3) · Sweden (3) · Switzerland (3) · Austria (2) · Israel (2) · Italy (2) · Norway (2)
John D. Hainsworth, MD (4) · Bin Cheng, Doctor (2) · Franco M. Muggia, MD (2) · Lillian Siu, MD (2) · Matthew P. Goetz, MD (2) · Philippe Bedard, MD (2) · Sridhar Mani, MD (2) · Afshin Shafie, MD (1) · Alwin Kraemer, Prof. Dr. (1) · Amol J. Ghia, MD (1) · Andre A. Abitbol, MD (1) · Anthony W. Tolcher, MD (1) · Aung Naing (1) · Ayman Gaber, MD (1) · Cai Grau, MD (1)
PMID 15855973, PMID 18494054, PMID 21420083, PMID 23433878, PMID 24578254, PMID 35262412, PMID 9087830, PMID 10228757, PMID 12393999, PMID 17470864, PMID 17643700, PMID 19117242, PMID 19965914, PMID 20164695, PMID 20209610, PMID 20407240, PMID 20432206, PMID 21299803, PMID 22218909, PMID 22284089, PMID 22815703, PMID 23006802, PMID 23086117, PMID 23433596, PMID 23641043, PMID 23670100, PMID 24937670, PMID 25303907, PMID 25733127, PMID 25965575, PMID 26279842, PMID 26422979, PMID 26578722, PMID 26646758, PMID 26879162, PMID 26919435, PMID 27071386, PMID 27575023, PMID 27782854, PMID 28733257, PMID 29149611, PMID 29343303, PMID 29539639, PMID 30054634, PMID 30261643, PMID 31533818, PMID 31932775, PMID 31953927, PMID 32188704, PMID 32303619
P30CA016087 (2), 2014 (1), 2017 (1), 2019 (1), N01CM00100 (1), P30CA006516 (1), P30CA006973 (1), P30CA013330 (1), P30CA016672 (1), P30CA021765 (1), P30CA023108 (1), P30CA047904 (1), P30CA069533 (1), P30CA072720 (1), R01CA266146 (1)